© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 8, 640-647,
April 21, 1993
© 1993 Oxford University Press
Acute Lung Injury Following Treatment With High-Dose Cyclophosphamide, Cisplatin, and Carmustine: Pharmacodynamic Evaluation of Carmustine
Bone Marrow Transplant Program, Division of Hematology/Oncology, University of Colorado Health Sciences Center Denver, Colo
Division of Pulmonary Diseases, Department of Medicine, University of Colorado Health Sciences Center Denver, Colo
Department of Pathology and the Cancer Center, University of Colorado Health Sciences Center Denver, Colo
Correspondence to: Roy B. Jones, Ph.D., M.D., Director, Bone Marrow Transplant Program, University of Colorado Health Sciences Center, Box B-190, 4200 East 9th Ave., Denver, Co 80262.
Background: Therapy with high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) plus autologous bone marrow transplantation has been extensively studied as treatment for patients with stage II or III breast cancer who have a 70% or greater risk of developing metastatic disease. This therapy is being used in a cooperative intergroup phase III clinical trial. In the cyclophosphamide-cisplatin-BCNU regimen, cyclophosphamide and BCNU, but not cisplatin, have been reported to cause acute lung injury, suggesting that either cyclophosphamide or BCNU may contribute to this injury. Purpose: The purpose of this study was to analyze clinical and pharmacokinetic data from our ongoing phase II trials and to determine whether there is an association between BCNU pharmacokinetics and acute lung injury following cyclophosphamide-cisplatin-BCNU therapy. Methods: We performed a retrospective study of 38 patients treated following induction therapy or relapse, 29 with stage II-IV breast cancer and nine with intermediate and high-grade stage III-IV non-Hodgkin's lymphoma. These patients received therapy with cyclophosphamide at a dose of 1875 mg/m2 daily as a 1-hour intravenous infusion for 3 days, cisplatin at 55 mg/m2 per day as a 72-hour continuous intravenous infusion, and BCNU at 600 mg/m2 as a 2-hour infusion immediately following completion of the cisplatin infusion. Data from analysis of blood samples were used to calculate pharmacokinetic parameters for BCNU, and acute lung injury was determined on the basis of pulmonary function test results and histologic examination of lung biopsy specimens. Results: Our analysis showed that 20 (53%) of the 38 patients developed pulmonary injury following treatment. Twelve (60%) of the 20 had values for area under the curve (AUC) for BCNU concentration x time that exceeded 600 (µg/mL) x minute, whereas only two (11%) of the 18 without pulmonary injury had values above this level (P<.03). Thus, 12 (86%) of 14 patients with BCNU AUC greater than 600 (µg/mL) x minute developed lung injury. Conclusions: These results suggest that BCNU exposure greater than 600 (µg/mL) x minute is associated with increased risk of acute lung injury after cyclophosphamide-cisplatin-BCNU therapy and may be a major cause of pulmonary drug injury following this regimen. Implications: Strategies aimed at more uniform drug exposure or selective neutralization of chlorethylisocyanate, one of the two major hydrolysis products of BCNU, might reduce the incidence of acute lung injury following this regimen without major compromise of antitumor effect. [J Natl Cancer Inst 85: 640–647, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Nieto, J. J. Vredenburgh, E. J. Shpall, S. I. Bearman, P. A. McSweeney, N. Chao, D. Rizzieri, C. Gasparetto, S. Matthes, A. E. Baron, et al. Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer Clin. Cancer Res., November 1, 2004; 10(21): 7136 - 7143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Bhalla and R. J. Folz Idiopathic Pneumonia Syndrome after Syngeneic Bone Marrow Transplant in Mice Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1579 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. P. Petros, G. Broadwater, D. Berry, R. B. Jones, J. J. Vredenburgh, C. J. Gilbert, J. P. Gibbs, O. M. Colvin, and W. P. Peters Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer Clin. Cancer Res., March 1, 2002; 8(3): 698 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nieto, S. Nawaz, R. B. Jones, E. J. Shpall, P. J. Cagnoni, P. A. McSweeney, A. Baron, C. Razook, S. Matthes, and S. I. Bearman Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer J. Clin. Oncol., February 1, 2002; 20(3): 707 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. BHALLA, S. W. WILCZYNSKI, A. M. ABUSHAMAA, W. P. PETROS, C. S. MCDONALD, J. S. LOFTIS, N. J. CHAO, J. J. VREDENBURGH, and R. J. FOLZ Pulmonary Toxicity of Induction Chemotherapy Prior to Standard or High-dose Chemotherapy with Autologous Hematopoietic Support Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 17 - 25. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Nieto, P. J. Cagnoni, E. J. Shpall, S. Matthes, A. Baron, R. B. Jones, and S. I. Bearman Phase II Trial of High-Dose Chemotherapy with Autologous Stem Cell Transplant for Stage IV Breast Cancer with Minimal Metastatic Disease Clin. Cancer Res., July 1, 1999; 5(7): 1731 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. P. Petros and O. M. Colvin Metabolic Jeopardy with High-Dose Cyclophosphamide?--Not So Fast Clin. Cancer Res., April 1, 1999; 5(4): 723 - 724. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Folz and M. A. Elkordy Coronavirus Pneumonia Following Autologous Bone Marrow Transplantation for Breast Cancer Chest, March 1, 1999; 115(3): 901 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nieto, P. J. Cagnoni, S. I. Bearman, E. J. Shpall, S. Matthes, T. DeBoom, A. Baron, and R. B. Jones Acute Encephalopathy: A New Toxicity Associated with High-Dose Paclitaxel Clin. Cancer Res., March 1, 1999; 5(3): 501 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. WILCZYNSKI, J. J. ERASMUS, W. P. PETROS, J. J. VREDENBURGH, and R. J. FOLZ Delayed Pulmonary Toxicity Syndrome following High-dose Chemotherapy and Bone Marrow Transplantation for Breast Cancer Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 565 - 573. [Abstract] [Full Text]
|
|